GMED
Globus Medical, Inc.
GMED's fundamentals are strong and it looks cheap: trading at 18x earnings, less than half its usual 41x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GMED Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
GMED's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GMED PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $72.30 | — |
| Current | 18x | $72.30 | — |
| Cheap | 26x | $106 | +46% |
| Fair | 41x | $166 | +129% |
| Expensive | 70x | $283 | +291% |
Historical ranges are pointers, not guarantees.
GMED's PE is in its cheap range at 18x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GMED Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect GMED's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GMED Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.18 | +28% |
| Q3 2026 | $4.05 | +31% |
| Q2 2026 | $3.89 | +50% |
| Q1 2026 | $4.28 | +219% |
| Q4 2025 | $3.92 | +423% |
| Q3 2025 | $3.10 | +349% |
| Q2 2025 | $2.60 | +713% |
| Q1 2025 | $1.34 | +103% |
| Q4 2024 | $0.75 | -37% |
GMED has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GMED Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $763.7M | -0.7% |
| Q2 2026 | $789.6M | +5.9% |
| Q1 2026 | $759.9M | +27% |
| Q4 2025 | $826.4M | +26% |
| Q3 2025 | $769M | +23% |
| Q2 2025 | $745.3M | +18% |
| Q1 2025 | $598.1M | -1.4% |
| Q4 2024 | $657.3M | +6.6% |
GMED's revenue is growing: $764M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +5.4 points |
| Q2 2026 | 23% | +13 points |
| Q1 2026 | 20% | +3.6 points |
| Q4 2025 | 20% | +11 points |
| Q3 2025 | 18% | +10 points |
| Q2 2025 | 10% | +2.3 points |
| Q1 2025 | 16% | +15 points |
| Q4 2024 | 9.2% | +7.5 points |
GMED has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GMED on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GMED Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $224.8M | +5.1% |
| Q2 2026 | $176.6M | +464% |
| Q1 2026 | $162.7M | +15% |
| Q4 2025 | $202.4M | +4.7% |
| Q3 2025 | $213.9M | +32% |
| Q2 2025 | $31.3M | +18% |
| Q1 2025 | $141.2M | +493% |
| Q4 2024 | $193.2M | +136% |
GMED has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
GMED Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -1.4M shares |
| 1 year | +0.5% | +623K shares |
| 3 years | +18% | +20.8M shares |
| 5 years | +30% | +31.6M shares |
| Available history | +33% | +34M shares |
GMED has 136M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $142.9M |
| Q2 2026 | $136.1M |
| Q1 2026 | — |
| Q4 2025 | $45M |
| Q3 2025 | $40M |
| Q2 2025 | $25M |
| Q1 2025 | $190.5M |
| Q4 2024 | $1M |
GMED spent $324M buying back its own shares over the past year, up 26% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GMED on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GMED Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.6x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.7x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.9x | Net Cash |
GMED has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GMED Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 15.8 | Oversold |
GMED's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GMED PE vs Healthcare Sector
| Metric | GMED | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 31% below |
| PE % | 0 | 29 | 29 pts below |
GMED is trading at 18x earnings, a 31% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GMED Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $75.5 | 4.3% below |
| 20 week MA | $78.0 | 7.3% below |
| 50 week MA | $83.6 | 14% below |
| 100 week MA | $76.5 | 5.5% below |
| 200 week MA | $68.5 | 5.6% above |
GMED has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GMED Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.9 | $65.3 | +11% |
| 2021 | $65.3 | $72.2 | +11% |
| 2022 | $72.2 | $73.9 | +2.3% |
| 2023 | $73.9 | $53.3 | -28% |
| 2024 | $53.3 | $83.6 | +57% |
| 2025 | $83.6 | $88.4 | +5.8% |
| 2026 YTD | $88.4 | $72.3 | -18% |
GMED has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.